Roivant Sciences SEC Filings

Rockefeller Financial LLC filed a Form 144 notice to sell 200,000 Common Shares of Roivant Sciences Ltd. The sale is described as resulting from an options exercise with grant date 04/20/2022 and the proposed transaction date 03/17/2026, with proceeds to be transmitted by wire.

The excerpt also lists recent sales by Eric Venker, including multiple transactions of 200,000 shares on 02/13/2026 and 01/12/2026 and smaller tranches on other dates; these prior sales are shown with corresponding gross amounts in the table.

Morgan Stanley Smith Barney LLC submitted a Form 144 notice for ROIV reporting restricted stock vesting events under a registered plan. The filing lists multiple vesting dates and per‑event share counts, including 13,580 shares vesting on 09/12/2024 and 14,745 shares vesting on 09/10/2025.

The entries are described as "Restricted stock vesting under a registered plan" with the issuer listed as the source of the vested shares. The filing documents the timing and share amounts of these compensation‑related vesting events rather than open‑market trades.

Roivant Sciences Ltd ownership filing: an amendment to a Schedule 13G/A reports that FMR LLC beneficially owns 73,641,253.25 shares of Roivant common stock, equal to 10.3% of the class. The filing states FMR LLC has sole dispositive power over 73,641,253.25 shares and shared voting power of 0.00. The cover also lists Abigail P. Johnson with sole dispositive power of 73,641,253.25 shares and a 10.3% ownership figure. The filing includes Item 6 disclosure that other persons may have rights to dividends or sale proceeds, and references an Exhibit 99 agreement and powers of attorney; signatures are dated 03/05/2026.

Roivant Sciences reported that its subsidiary Genevant Sciences and partner Arbutus Biopharma entered into a $2.25 billion global settlement with Moderna to resolve all U.S. and international patent disputes over lipid nanoparticle technology used in COVID-19 vaccines, including Spikevax.

Under the settlement, Moderna will pay Genevant/Arbutus a $950 million noncontingent lump sum on or before July 8, 2026, plus a potential $1.3 billion contingent lump sum depending on the outcome of an appeal relating to 28 U.S.C. § 1498, with possible prorating and repayment mechanics if later overturned. The agreement also grants Moderna a fully paid-up, royalty-free, irrevocable, non-exclusive worldwide license and covenants not to sue for specified vaccines and patents.

Roivant’s board also expanded its common share repurchase program to up to $1.0 billion, inclusive of a previously announced $500 million authorization. Repurchases, funded from cash and cash equivalents, may occur via tender offers, open-market purchases, or privately negotiated transactions and can be suspended or discontinued at any time.

Roivant Sciences, through its subsidiary Priovant Therapeutics, announced that the FDA has accepted the New Drug Application for brepocitinib to treat dermatomyositis and granted it Priority Review. The FDA set a PDUFA target action date in the third quarter of 2026, and the company expects a U.S. launch at the end of September 2026 if approved.

The Priority Review decision is based on positive Phase 3 VALOR data in 241 patients, where the 30 mg dose showed statistically significant and clinically meaningful improvement over placebo on the primary Total Improvement Score endpoint at Week 52 and all nine key secondary endpoints. Safety data across more than 2,000 subjects suggest a profile similar to approved JAK and TYK2 inhibitors, although serious infections were more frequent with the 30 mg dose and required medical management.

Roivant Sciences Ltd. reported that CFO Richard Pulik had 1,000 common shares withheld at a price of $27.15 per share to cover tax obligations from the vesting of previously granted RSUs. After this tax-withholding disposition, he directly holds 238,413 common shares.

Roivant Sciences Ltd. President & Immunovant CEO Eric Venker reported a Form 4 showing a tax-related share disposition. On this date, 7,051 common shares were withheld and net-settled by the company to satisfy tax withholding obligations arising from the vesting of previously granted RSUs. After this tax-withholding disposition, Venker directly owned 1,647,546 common shares.

Roivant Sciences Ltd. President and Vant Chair Frank Torti reported a series of stock option exercises and related share sales. Between February 19 and 23, he exercised options to acquire a total of 3,000,000 Common Shares at an exercise price of $3.85 per share and then sold the same number of shares in open-market transactions.

The sales covered 1,400,000, 1,012,610, and 587,390 Common Shares at weighted average prices of $27.42, $27.15, and $27.51 per share, respectively, with individual trades occurring between $26.70 and $27.80. After these transactions, Torti directly owned 13,736,547 Common Shares and held 3,026,184 stock options.

Frank M. Torti filed a Form 144 disclosing an intended sale of 1,600,000 shares of common stock of the issuer ROIV on 02/20/2026 tied to an exercise of stock options. The filing shows an aggregate value of $44,032,000 and identifies Morgan Stanley Smith Barney LLC as broker.

The filing also records prior 10b5-1 sales by Mr. Torti of 1,400,000 shares on 02/19/2026 with proceeds of $38,392,834.26. Transaction mechanics are shown as cash proceeds from option exercise.